search button

Breast cancer cells evade paclitaxel-induced cell death by developing resistance to dasatinib

  • Authors:
    • Yun‑Ji Jeong
    • Jong Soon Kang
    • Su In Lee
    • Dong Min So
    • Jieun Yun
    • Ji Young Baek
    • Sang Kyum Kim
    • Kiho Lee
    • Song‑Kyu Park

  • View Affiliations

  • Published online on: July 13, 2016     https://doi.org/10.3892/ol.2016.4852
  • Pages: 2153-2158
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Triple negative breast cancer (TNBC), which does not express the progesterone, estrogen, or HER2/neu receptor, is aggressive and difficult to treat. Paclitaxel, a tubulin stabilizing agent, is one of the most frequently prescribed anticancer agents for breast cancers, including TNBC. Residual disease that occurs due to resistance or partial resistance of cancer cells in a tumor against anticancer agents is the most important issue in oncology. In the present study, when MDA‑MB‑231 cells, a TNBC cell line, were treated with 30 µM paclitaxel, a slightly higher concentration than its GI50 value, for 6 days, a small number of cells with different morphologies survived. Among the surviving cells, small round cells were isolated, cloned, and named MDA‑MB‑231‑JYJ cells. MDA‑MB‑231‑JYJ cells were observed to be highly proliferative and tumorigenic. In addition, signal transduction molecules involved in proliferation, survival, malignancy, or stemness of cancer cells, such as c‑Src, c‑Met, Notch 1, c‑Myc, Sox2, Oct3/4, Nanog, and E‑cadherin were highly expressed or activated. While further study is required, MDA‑MB‑231‑JYJ cells appear to have some of the characteristics of cancer precursor cells. Although MDA‑MB‑231‑JYJ cells were isolated from the cells that survived in the continuous presence of paclitaxel, they were not resistant to paclitaxel but developed resistance to dasatinib, a Bcr‑Abl and Src kinase family inhibitor. The activated state of Src and Notch 1, and the expression levels of c‑Myc and cyclins in MDA‑MB‑231‑JYJ cells were less affected than MDA‑MB‑231 cells by the treatment of dasatinib, which may explain the resistance of MDA‑MB‑231‑JYJ cells to dasatinib. These results suggest that cancer cells that become resistant to dasatinib during the process of paclitaxel therapy in patients may appear, and caution is required in the design of clinical trials using these two agents.
View Figures
View References

Related Articles

Journal Cover

September-2016
Volume 12 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Jeong YJ, Kang JS, Lee SI, So DM, Yun J, Baek JY, Kim SK, Lee K and Park SK: Breast cancer cells evade paclitaxel-induced cell death by developing resistance to dasatinib. Oncol Lett 12: 2153-2158, 2016.
APA
Jeong, Y., Kang, J.S., Lee, S.I., So, D.M., Yun, J., Baek, J.Y. ... Park, S. (2016). Breast cancer cells evade paclitaxel-induced cell death by developing resistance to dasatinib. Oncology Letters, 12, 2153-2158. https://doi.org/10.3892/ol.2016.4852
MLA
Jeong, Y., Kang, J. S., Lee, S. I., So, D. M., Yun, J., Baek, J. Y., Kim, S. K., Lee, K., Park, S."Breast cancer cells evade paclitaxel-induced cell death by developing resistance to dasatinib". Oncology Letters 12.3 (2016): 2153-2158.
Chicago
Jeong, Y., Kang, J. S., Lee, S. I., So, D. M., Yun, J., Baek, J. Y., Kim, S. K., Lee, K., Park, S."Breast cancer cells evade paclitaxel-induced cell death by developing resistance to dasatinib". Oncology Letters 12, no. 3 (2016): 2153-2158. https://doi.org/10.3892/ol.2016.4852